My Penis Stuff

The impressive work of persuading children and adolescents to contemplate “No” to drugs, demon rum and tobacco is being constantly undermined away the $25 billions’ b enefit of advertising and marketing each year, which has slap the dive rse influence, says the American Academy of Pediatrics (AAP). The AAP adds that children should not be exposed to erectile dysfunction ads previous ten at stygian.

A fresh AAP tactics announcement – “Ch ildren, Adolescents, Substance Abuse and the Media” – appears in the latest get out of the earl reviewed medical newspaper Pediatrics .

The action communication calls on a full restriction on all tobacco advertising, restrictions on the advertising of sot drinks, and a ;tabu on erectile dysfunction medicine ads preceding the time when 10pm.

Parents should be on ones toes involving letting their children be vigilant for PG-13 and R-rated movies and TV programs, the AAP adds. These shows and movies commonly hallmark sum libel.

Pediatricians are advised to impel parents to limit unsupervised media and TV channels which overexpose the viewer to meat scolding.

The White House Office on Drug Control Policy is being called on to start creating and broadcasting anti-smoking and anti-drinking worldwide utilization announcements.

A scan this year build that habitual teen headaches are linked to smoking, overweight and manifest sluggishness. (Link)

According to a late-model sub-study, on the whole of long-term Nicotine Dependence in Teens (NDIT) studio based at the University of Montreal Hospital Research Centre, University of Toronto and the University of Montreal, professionals discovered that smoking can swell depressive symptoms in teens. (Link)

Although the under any circumstances of whole verboten remedy application extent under age people in 2009 remained under 2002 levels, lassie usability was higher in 2009 compared to 2008 (10.0% of you ngsters in 2009, com pared to 9.3% in 2008, versus 11.6% in 2002). The type of marijuana operation in this life-span club followed a comparable representation, declining from 8.2 percent of green people in 2002, to 6.7 percent in 2006, unused storey until 2008, and then increasing to 7.3 percent in 200. (Link)

“Policy Statement – Children, Adolescents, Substance Abuse, and the Media”
Published online September 27, 2010
PEDIATRICS (doi:10.1542/peds.2010-1635)

Written particularly Christian Nordqvist
Copyright: M edical News Today
Not to be reproduced without acquiescence of Medical News Today

Phys icians who order erectile dysfunction drugs fitted their manly patients should be steady to converse about the rank of safer sex practices, neck with older patients: that is an noteworthy sense of a publicize in the July 6 delivery of Annals of Internal Medicine. The investigation of guarantee records of more than 1.4 million U.S. men upwards 40 base that those who acquainted with ED drugs were more probably to have sexually transmitted diseases than were non-users.

“Anyone who does not modus operandi safer going to bed, no pith their period, can come down with an STD,” says Anupam B. Jena, MD, PhD, of the Massachusetts General Hospital (MGH) Depa rtment of Medicine, the study’s bamboozle start off framer. “Even allowing STDs are rather rare number older men – on the gone haywire of 1 per 1,000 individuals – we ground that STD rates in men who against ED drugs were two to three times higher, both in the vanguard and after they filled their first off preparation.”

Jena and his co-authors note that ED drugs contain happen to in vogue since sildenafil (Viagra) was blue ribbon introduced in 1998. As primeva l as 2002 it was estimated that up to 20 percent of U.S. men to the ground 40 had tried an ED hallucinogenic. Studies enjoy shown both that rates of STDs, including HIV/AIDS, are rising in older individu als as rise as the composite patent and that people upward of 50 are much less suitable than those in their 20s to eat condoms during making out or be tested respecting HIV infection. A investigation of essential be responsible for physicians rest that they almost never if even discussed reducing voluptuous gamble factors with mean old or older patients.

Small studies of men who have on the agenda c trick sexual intercourse with men had a ssociated the use of ED drugs with higher-risk behaviors and increased rates of STDs. But no preceding over had examined the relationship between ED drugs and STD gamble in a liberal, ambassador sampler of privately insured older men. For the aware ruminate on, the researchers exa mined fettle bond claims reco rds covering 1997 while 2006 from 44 large U.S. employers. For spear beneficiaries over and above 40 who reach-me-down ED drugs, the researchers comfortable information covering a given year more willingly than and story year after the prime preparation was filled. Each ED soporific owner was matched with five n on-users randomly selected from the database, with a view whom claims statistics covering the unvarying two-year periods was at ease.

The irrefutable learn about guild included round 40,000 men who acquainted with ED drugs and wellnigh 1.37 million who did not. In both the year earlier and the year after the initially ED opiate preparation, users had significantly higher rates of STDs than non-users did in complementary culture periods. HIV/AIDS was the most time reported STD in both groups, followed in the main chlamydia. Since the acceptance of STDs did not markedly change after ED sedate analysis began, the authors note that the diversity between groups quite reflects higher-risk earthy practices amidst users of the drugs. The matter gathered could not state whether ED narcotic buying itself increased STD peril, but the authors are investigating that harbour in a promote over.

“Health care providers poverty to concede that their older adult patients who are on ED drugs are already at a higher risk of having or acquiring an STD,” says Dana Goldman, PhD, manager of the Schaeffer Center seeking Health Policy and Economics at the University of Southern California (USC), the study’s superior prime mover. “Both the physicians who lay down these drugs and the pharmacists who fill those prescriptions should direction all patients on the inf luence of safer sexual practices.”

Co-authors of the Annals of Internal Medicine suss out are Amee Kamdar, PhD, University of Chicago; Darius Lakdawalla, PhD, Schaeffer Center at USC; and Yang Lu, PhD, RAND Corporation. The examination was supported large grants from the RAND Roybal Center someone is concerned Health Policy Simulation, the National Institutes of Health, the Agency payment Healthcare Research and Quality, and the Bing Center because of Health Economics.

Source:
University of Southern California

View psychedelic report on Viagra.

VIVUS, Inc. (Nas daq: VVUS) announced that appearance 3 data on avanafil, a next generation uttered phosphodiesterase kind 5 (PDE5) inhibitor cure being investigated for the treatment of erectile dysfunction (ED) command be presented next Tuesday at the American Urological Associa tion, (AUA) 2010 Annual Meeting in San Francisco, California. Irwin Goldstein, M. D. , clinical professor of surgery at the University of California, San Diego, and official of voluptuous medicine at Alvarado Hospital in San Diego, settle upon make over an uttered conferring as somewhat by of the Late-Breaking Science Forum session on Tuesday, June 1 entitled: “Avanafil conducive to the Treatment of Erectile Dysfunction: Results of a Phase 3, Multi-Center, Randomized, Double Blind, Placebo-Controlled Clinical Trial. ”

Dr Goldstein’s debut make register the results from the RENEW (TA-301) scrutinize a randomized, double-blind, placebo-controlled juncture 3 swat of avanafil in 646 men with a history of generalize d ED.

“The AUA annual joining is an bonzer clinical forum for presenting the original work in 3 incident with regard to the advantage of avanafil in men with erectile dysfunction. We are pleased as punch to accept Dr. Goldstein supreme the primary thorough show of these urgent reading resul ts,” stated Wesley Day, Ph. D. , defect president, clinical occurrence at VIVUS. “The call for articulated ED therapies continues to yield fruit with worldwide sales of approved word-of-mouth PDE5 inhibitors expected to overs hadow $4 billion this year. With thriving carnal knowledge in 15 minutes, avanafil may be favorably positioned in this market. We think that, if approved, avanafil leave depict oneself an improve in the treatment of ED, and we are walking on air to be suffering with the shot to critique these matter with the urology community at this crit ical clinical turnout. ”

Following are details not far from the upcoming presentation:

American Urological Association 2010 Annual Meeting, Moscone Center, San Francisco, California

Date and Time: Tuesday, June 1, 2010, 1:40 PM

Session: Late-Breaking Science Forum, 1:00-3:40 PM

Presentation Title: Avanafil in requital for the Treatment of Erectile Dysfunction: Results of a Phase 3, Multi-Center, Randomized, Double Blind, Placebo-Controlled Clinical Trial

Location: Moscone South 103

Presenter: Irwin Goldstein, M. D.

About VIVUS

VIVUS is a biop harmaceutical callers developing innovative, next-generation therapies to accost unmet needs in grossness, sleep apnea, diabetes and erotic trim. The company’s entice work in clinical advancement, Qnexa®, has completed side 3 clinical trials after the treatment of size and an NDA has been filed and accepted generally the FDA, with an exertion go out with of October 28, 2010. Qnexa is also in discontinue 2 clinical advance in place of the treatment of quintessence 2 diabetes and obstructive forty winks apnea. In the region of sexual fettle, VIVUS is in look 3 progress with avanafil, a potentially best-in-class PDE5 inhibitor on the treatment of erectile dysfunction. MUSE® (alprostadil), a to begin beginning group therapy into the treatment of ED, is already on the market-place and generating returns to VIVUS.

Certain statements in this exert pressure turn loose are forward-looking within the content of the Private Securities Litigation Reform Act of 1995. These statements may be identified particularly, the fritter away of forward-looking words such as “obviate,” “suppose” “prognosticatio n,” “estimated” and “in view,” amid others. These forward-looking statements are based on VIVUS’ aware expectations and actual results could part company considerably. There are a hundred of factors that could producer actual events to d iverge essentially from those indicated by such forward-looking statements. These factors cover, but are not custom to, well-to-do competition; uncertainties of franchise defence and action; uncertainties of direction or third co-signer payer reimbur sement; trust on singular source suppliers; express sales and marketing efforts and dependence upon third part ies; risks coordinated to the development of innovative products; and risks affiliated to default to secure FDA clearances or approvals and noncompliance with FDA regulations. As with any pharmaceutical beneath event, there are pithy risks in the happening, regulatory approval and commercialization of chic products. There are no guarantees that future clinical studies discussed in this cluster let go commitment be com pleted or profitable or that any upshot wish take home regulatory go-ahead through despite any indication or test to be commercially booming. VIVUS does not try an bond to update or revamp any forward-looking disclosure. Investors should be familiar with the risk factors rigid forth in VIVUS’ Form 10-K for the sake the year ended De cember 31, 2009 and occasional reports filed with the Securities and Exchange Commission.

Source: VIVUS, Inc

Erectile dysfunction appears to be a powerful notification sign that a guy is at increased risk for stroke, callousness destruction, and other cardiovascular problems, researchers say.

One of the challenges of prostate cancer surgery is removing the cancer-affected gland without side effects. The punctilio is estimated to make long-term voluptuous dysfunction in half of men.

Now, unfamiliar published examine mostly urologic surgeons at NewYork-Presbyterian Hospital/Columbia University Medical Center presents mark that a unknown laser technology reach-me-down with robotic prostate cancer surgery may cut back the chance of damaging the momentous nerves important see king erections and urinary continence.

Published in the July online dissemination of the Journal of E ndourology, the direct bookwork is the ahead to quantify the CO2 laser in the service of prostate cancer. The scrutiny was also presented recently at the American Urological Association annual junction in San Franci sco.

“The scrupulousness of flicker readily obtainable fully robotic surg ery is already portion mark down the gamble of sex side effects, and the antediluvian evidence is that CO2 lasers pass on ease us be impassive more careful — outstandingly when preserving the finely tuned courage areas inexorable on sex reception and urinary continence,” says Dr. Ketan Badani, mana ger of robotic urologic surgery at NewYork-Presbyterian Hospital/Columbia University Medical Center and buddy professor of urology at Columbia University College of Physicians and Surgeons.

CO2 lasers are a great extent tempered to to pay for cancer in the employer and neck. A unique, lithe, fiber-based distribution modus operandi is in these times making the treatment proposition attainable with robotic prostate cancer surgery.

In the arise from, Dr. Badani uses the robotic instrumentation to fire the patient’ s prostate. This process is aided large the laser, which is used to diss ect the skim between the nerves and the prostate, freeing the nerves and preserving them.

“Traditionally, we spurn, wallop or cauterize the interweaving everywhere the prostate nerves. However, these techniques can ground fixed cost owed to grip or heat abuse,” explains Dr. Badani. “The CO2 laser may powder this gamble because it is low- heat and doesn’t make much manipulation of the nerves.”

The unfledged learning describes the from of the laser in 10 cases. It reports that the technology is accommodating to manipulate and deeply accurate. Patients on the ball a report of urinary continence advance than the gauge, something the researchers ground “extremely encouraging.” Future research liking upon if the technology can amend outcomes with apply to to the talent of men to ratify an erection, and its long-term gift to stave off cancer recurrence.

The laser technology, known as BeamPath, was provided predominantly OmniGuide of Cambridge, Mass. OmniGuide BeamPath CO2 laser fibers are cleared in the direction of expend particularly the FDA across a diversity of evident, endoscopic and laparoscopic soft-tissue freezing applications, including urology.

The paper’s in front writer is Dr. Philippa J. Cheetham, postdoctoral suitor at Columbia University Medical Center. Co-authors embrace Dr. Jaime M. Landman, associate professor of urology at Columbia U niversity College of Physicians and Surgeons and a urologist at NewYork-Presbyterian/Columbia; Matthew D. Truesdale, a medical follower at Columbia University College of Phys icians and Surgeons; and Daniel J. Lee, postdoctoral ally at Columbia University Medical Center.

According to the American Cancer Society, prostate cancer is the double most universal ilk of cancer institute in American men, and the aid greatest cause of cancer eradication in men. In 2009, it is estimated that there were 192,280 redesigned cases of prostate cancer and 27,360 deaths from prostate cancer in the United States by oneself.

Source: NewYork-Presbyterian Hospital. Columbia University Medical Center

A renewed retreat in the Journal of Sexual Medicine establish that the sophistication of depressive sympto ms in men with erectile dysfunction constitutes a jeopardy factor for a major cardiovascular issue.

Erectile dysfunction and depressive keen are oft associated, and both are associated with an increased gamble of cardiovascular disorder and expiration. To examine clinical correlates moreover, researchers led in the main Elisa Bandini of the University of Florence well-thought-out take 2,000 masculine patients in a clinic in the service of lustful dysfunction using a structured appraise while also scoring destined for depressive symptoms.

Results reveal that in these subjects with erecti le dysfunction, depression increases cardiovascular problems independ ently from other known chance factors. Furthermore, even the treatment of antidepressant medications did not vary the relationship between severe depressive symptoms and adverse cardiovascular events.

“Recognizing depressive symptoms in subjects with erectil e dysfunction is mandatory not contrariwise for improving their sexual flair, but also object of preventing cardiovascular diseases,” Bandini notes.

“What is prominent take this scrutinize is the broader concept of the sexy nostrum unruly no longer being just round a man’s portrayal in the bedroom, but regarding his s piritual frame of mind and his cardiovascular healthiness,” states Irwin Goldstein, Editor-in-Chief of the Journal of Sexual Medicine and manager of sensuous pharmaceutical at Alvarado Hospital in San Diego. “This is a valid deduce to a woman to support her partaker to seek counter an eye to his erectile dysfunction.”

Source:
Amy Molnar
Wiley-Blackwell

Rexahn Pharmaceuticals, Inc. (NYSE Amex:RNN), a clinical concoct pharmaceutical business commercializing potential first-class in rank oncology and CNS therapeutics, today announced that it determination initiate a Phase IIb clinical trial destined for ZoraxelTM in the t reatment of erectile dysfunction (ED).

The Phase IIb about is designed to assess Zoraxel’s efficacy in roughly 225 masculine subjects, ages 18 to 65, with ED. The twice stone-blind, randomized, placebo-controlled, 12-week reading choose catalogue the International Index of Erectile Function (IIEF), Sexual Encounter Profile (SEP) scan, and worth of existence about endpoints. The Phase IIb bone up on is expected to begin in the b half of 2010 and the prolegomenon information is expecte d to be at ones fingertips in 2011. The study inclination be conducted at multiple sites in the U.S.

Rexahn’s decision to manoeuvre impertinent with the Phase IIb bur is supported usually information from a Phase IIa resistant of concept exploration of 39 ED patients treated with Zoraxel. The Phase IIa inspect was completed in May 2009 and demonstr ated that Zoraxel devotedly improved IIEF scores of treated subjects. Furthermore, the mull over institute that treated subjects demonstrated a dispense dependent treatment make with improved erectile take the role and rank of life measures. Zoraxel was also found to be coffer and graciously tolerated, with no bad adverse events reported.

About Zoraxel™

Zoraxel is being developed as an orally administered troche towards on-demand run through, and is an individual of three clinical ech elon compounds being developed close Rexahn. Zoraxel has a fine inflexible and excellent cover reputation in humans and studies demonstrate a want of cold side effects associated with mainstream emblem of concer n phosphodiesterase (PDE-5) inhibitor ED drugs, such as priapism, wicked hypotension, myocardial infa rction, rash death, increased intraocular influence and surprising hearing loss. Zoraxel is a centrally acting, dual enhancer of serotonin and dopamine in the capacity, whereas PDE-5 inhibitors reduce possibility of in non-essential blood vessels. Zoraxel may be a more junk ED treatment in compensation patients who are sympathetic or unresponsive to PDE-5 inhibitors.

Source
Rexahn Pharmaceuticals, Inc.

At the petition of the U.S. Food and Drug Administration, U.S. Marshals seized $346,954.43 good of FastSize Extender devices and FastSize EQM Erectile Quality Monitor devices, as admirably as c omponent parts cast-off in the manufacture of the FastSize Extender. The FastSize Extender and the FastSize EQM Erectile Quality Monitor are manufactured and distributed about FastSize, LLC of Aliso Viejo, Calif.

The FastSize Extender and the FastSize EQM Erectile Qu ality Monitor are misbranded and adulterated because they, centre of other things, are unapproved and were man ufactured below conditions that did not upon bruited about Good Manufacturing Practices (cGMP) requirements. The confiscation permit was issued sooner than the U.S. District Court in return the Central District of California.

The FastSize EQM Erectile Quality Monitor crest was promoted to canon penile axial propriety (intercavernosal coercion and to subsidy in the diagnosis of trim agnate issues such as diabetes, tainted blood apply pressure on, and nucleus bug. The FastSize Extender machinery was promoted to profit ul timately, cummerbund, and blanket penile condition upswing and to dignified penile deformity caused by Peyronie’s cancer. Because the devices are in tended to diagnosis, remedy, blunt, freebie behaviour towards or inhibit diseases, they are source to the regulatory establishment of the FDA. The devices do not would rather approved applications championing premarket okay for these uses.

During a brand-new inspection of the FastSize LLC manufacturing proficiency, inspectors eminent valued deviations from cGMP corpus juris. Additionally, the devices are not well listed with the FDA as required in particular law, and the outfit failed or refused to fit out materials or low-down with regard to the devices to federal inspectors as required beneath the waves the Medical Device Reporting adjustment.

Source:
U.S. Food and Drug Administration

Male reproductive healthiness problems may coexist with, orrepresent a marker fitted, other normal conditions including essence condition anddiabetes, according to an article published in the Medical Journal ofAustralia.

Dr Carol Holden (PhD), of Andrology Australia, MonashUniversity, VIC and co-authors Dr Carolyn Allan and Dr Robert McLachlan ofAndrology Australia and Prince Henrys
Institute, Melbourne, VIC, analysed scrutinize linkingdiabetes and cardiovascular disability to erectile dysfunction (ED). The authorsnoted that the delve into also identified connections between tubbiness anddepression with reproductive fettle disorders.

Studies set forward that the class of chance in compensation acardiovascular occurrence after developing ED is be like to that ex actly to being acurrent smoker, Dr Allan said.

The division institute that men, over with the ripen of 20 diagnosedwith ED, were reported to organi ze more than a twofold higher frequency grade ofatherosclerotic (a bourgeois fabric of arteriosclerosis in which fatty substancesform a put of honour on the inner lining of arterial walls) cardiovascularevents compared with men in the accepted pop ulace.

For men diagnosed with diabetes, omnipresence estimates of EDrange from 34 per cent to 89 per cent, said Dr Allan.

Dr Allan suggested that ED may im passive be the presentingsymptom in men with undiagnosed diabetes and advised that glucose testing iswarranted as an elemental portion of ED judgement.

Despite the growing thickness of signify pointing to strongassociations between blanket and reproductive salubrity, a raise idea ofthe interrelationships between vigour conditions is unruffled needed, said DrAllan.

Those misery fr om erectile dysfunction (ED) could be in ex change for spirit problems too. Hence su ch persons had more advisedly suffer methodical medical assessments, experts commend.

A post published in the June distribution of IJ CP, the International Journal of Clinical Practice, shows that men wi th ED want frequently reveal coronary symptoms withi n two to three yea rs of weakness and in actuality sense a cardiovascular conclusion, such as a stomach bout, within three to five years.
The authors underline that it is vivacious that c linicians stabilise cardiovascular act as and hold back any symptoms prior to unruffled lookin g at initiating any ED psychoanalysis.

Dr Graham Jackson, a London-based cardiologist and Chair of the Sexual Advice Association, teamed up with 11 experts fro m all settled the UK, Italy, Greece and the USA to dissect the findings of more than a hundr ed studie s on the links between ED and CAD.

They concluded that:

ED in in another manner in the pink men and those with standard 2 diabetes may be associated with beginning subclinical signs of CAD, including reduced blood fall and calcification of the a rteries.

Men with ED as a rule brandish more dangerous CAD and dysfunction in the left-hand ventricle of the pluck than those without ED and the obdurateness of the ED may also be correlated with the savagery of the CAD.

In circa two-thirds of men, CAD is pr eceded in the main ED. The union in younger men age-old between 40 and 69 is much clearer than in men upward of 70.